pdufa.bio

RHHBY FDA decision dates

Page updated ·next FDA decision on the calendar ·Data as of Oct 14, 2026 7:39 PM ET

RHHBY has 3 upcoming FDA decision dates; the nearest is Oct 15, 2026 for Enspryng (satralizumab) - (thyroid eye disease). 12 past decisions are on record below, each on its own page. One event, one page: past decisions never share a URL with a live catalyst.

RHHBY catalyst hub · full calendar

Upcoming

Oct 15, 2026 in 1 dayEnspryng (satralizumab) - (thyroid eye disease)Nov 30, 2026 in 47 daysGiredestrant (lidERA)Dec 18, 2026 in 65 daysGiredestrant (+ everolimus)

Decided

Oct 8, 2026 ✓ ApprovedTecentriq (atezolizumab)Sep 25, 2026 ✓ ApprovedGazyva (obinutuzumab)Feb 20, 2026 ✓ ApprovedCALQUENCE plus venetoclaxDec 22, 2025 ✓ ApprovedLunsumio VELONov 25, 2025 ✓ Approvedprice-onlyOct 20, 2025 ✓ Approvedprice-onlyOct 2, 2025 ✓ ApprovedZepzelcaJul 18, 2025 CRLprice-onlyMay 22, 2025 ✓ ApprovedSusvimoMar 3, 2025 ✓ ApprovedTNKaseFeb 12, 2025 ✓ ApprovedEVRYSDIFeb 4, 2025 ✓ ApprovedSusvimo